EIGR:NAS (USA) Also trade in: Germany

Eiger BioPharmaceuticals Inc

$ 11.03 -2 (-15.35%)
Volume: 1,275,783 Avg Vol (1m): 105,743
Market Cap $: 212.44 Mil Enterprise Value $: 137.71 Mil
P/E (TTM): 0.00 P/B: 3.02
Earnings Power Value 4
Net Current Asset Value 3.67
Tangible Book 3.71
Projected FCF -12.45
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 5/10

Current vs industry vs history
Cash-to-Debt 3.92
Debt-to-Equity 0.39
Debt-to-EBITDA -0.51
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.71
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC 0%
WACC 7.15%

Profitability & Growth : 3/10

Current vs industry vs history
ROE % -140.16
ROA % -81.29
ROC (Joel Greenblatt) % -43914.04
3-Year Total EBITDA Growth Rate -56.80
3-Year EPS w/o NRI Growth Rate 60.50

» EIGR's 30-Y Financials

Financials (Next Earnings Date: 2019-05-10)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:EIGR

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325414    SIC : 2836
Compare OTCPK:CYDY FRA:PB9 NAS:KRYS NAS:LPTX ROCO:4193 TSE:4572 OSTO:MVIR B OTCPK:NWBO TPE:1733 NAS:KALV LSE:DDDD XPAR:GNRO OSL:TRVX NAS:OPHT ASX:MDC TSX:APS NAS:MACK XMCE:ORY NAS:CDTX NAS:TRVN
Traded in other countries 72C1.Germany
Address 350 Cambridge Avenue, Suite 350, Palo Alto, CA, USA, 94306
Eiger BioPharmaceuticals Inc is a clinical stage biopharmaceutical company. It is focused on bringing to market novel product candidates for the treatment of orphan diseases. The company's pipeline includes five Phase 2 development programs addressing four distinct orphan diseases. The pipeline includes lonafarnib for Hepatitis Delta Virus, or HDV, PEG-interferon lambda-1a (lambda) for HDV, exendin 9-39 for Post-Bariatric Hypoglycemia, or PBH and ubenimex for Pulmonary Arterial Hypertension, or PAH and lymphedema.

Ratios

Current vs industry vs history
PB Ratio 3.02
EV-to-EBIT -2.73
EV-to-EBITDA -2.73
Current Ratio 10.16
Quick Ratio 10.16

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -104.60

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 2.97
Earnings Yield (Joel Greenblatt) % -36.36

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N